CU20080161A7 - Composiciones que comprenden células madres de tejidos seleccionados y métodos de preparación - Google Patents

Composiciones que comprenden células madres de tejidos seleccionados y métodos de preparación

Info

Publication number
CU20080161A7
CU20080161A7 CU2008000161A CU20080161A CU20080161A7 CU 20080161 A7 CU20080161 A7 CU 20080161A7 CU 2008000161 A CU2008000161 A CU 2008000161A CU 20080161 A CU20080161 A CU 20080161A CU 20080161 A7 CU20080161 A7 CU 20080161A7
Authority
CU
Cuba
Prior art keywords
factor
relates
stem cells
compositions
preparation methods
Prior art date
Application number
CU2008000161A
Other languages
English (en)
Spanish (es)
Inventor
Geeta Shroff
Original Assignee
Geeta Shroff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geeta Shroff filed Critical Geeta Shroff
Publication of CU20080161A7 publication Critical patent/CU20080161A7/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/31—Pituitary sex hormones, e.g. follicle-stimulating hormone [FSH], luteinising hormone [LH]; Chorionic gonadotropins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C12N2501/392—Sexual steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
CU2008000161A 2006-03-07 2008-09-05 Composiciones que comprenden células madres de tejidos seleccionados y métodos de preparación CU20080161A7 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN582DE2006 2006-03-07
IN1500DE2006 2006-06-26
PCT/IB2007/002292 WO2007141657A2 (en) 2006-03-07 2007-03-06 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation

Publications (1)

Publication Number Publication Date
CU20080161A7 true CU20080161A7 (es) 2012-11-15

Family

ID=54150153

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2008000161A CU20080161A7 (es) 2006-03-07 2008-09-05 Composiciones que comprenden células madres de tejidos seleccionados y métodos de preparación

Country Status (23)

Country Link
US (9) US10545135B2 (pt)
EP (11) EP2422794A3 (pt)
JP (2) JP5649786B2 (pt)
KR (2) KR101505202B1 (pt)
CN (2) CN101420964A (pt)
AP (1) AP2949A (pt)
AU (1) AU2007257594B2 (pt)
BR (1) BRPI0708576A2 (pt)
CA (1) CA2644922C (pt)
CR (1) CR10345A (pt)
CU (1) CU20080161A7 (pt)
DK (1) DK1993575T3 (pt)
EA (1) EA027648B9 (pt)
EC (1) ECSP088799A (pt)
GE (1) GEP20135796B (pt)
IL (1) IL193702A (pt)
MA (1) MA30323B1 (pt)
MX (1) MX347303B (pt)
MY (1) MY154677A (pt)
NO (1) NO20084181L (pt)
NZ (2) NZ594639A (pt)
PH (1) PH12014501028A1 (pt)
WO (1) WO2007141657A2 (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2422794A3 (en) 2006-03-07 2013-03-13 Geeta Shroff Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
EP2137300B1 (en) 2007-04-26 2011-10-26 Ramot at Tel-Aviv University Ltd. Pluripotent autologous stem cells from oral or gastrointestinal mucosa
JP5567476B2 (ja) * 2007-05-28 2014-08-06 モナッシュ ユニバーシティ 慢性肺疾患の治療
US20090291061A1 (en) * 2008-05-21 2009-11-26 Riordan Neil H Stem cell therapy for blood vessel degeneration
RU2364382C1 (ru) * 2008-05-29 2009-08-20 Федеральное государственное учреждение "МОСКОВСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ ИМЕНИ ГЕЛЬМГОЛЬЦА ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ВЫСОКОТЕХНОЛОГИЧНОЙ МЕДИЦИНСКОЙ ПОМОЩИ" Способ повышения функциональной активности сетчатки при ее патологии различного генеза
BRPI0909866B1 (pt) * 2008-06-11 2021-08-24 Fresenius Medical Care Deutschland Gmbh Método de produção de um meio condicionado de células progenitoras de fígado, meio condicionado e composição farmacêutica
US20100010087A1 (en) * 2008-07-10 2010-01-14 Hong John J Methods for Inducing Stem Cell Migration and Specialization with EC-18
RU2385746C1 (ru) * 2008-07-18 2010-04-10 Владимир Алексеевич Шатров Способ лечения детского церебрального паралича
PL2356227T3 (pl) * 2008-11-14 2018-07-31 Viacyte, Inc. Kapsułkowanie komórek trzustki pochodzących z ludzkich pluripotencjalnych komórek macierzystych
GB201111244D0 (en) * 2011-06-30 2011-08-17 Konink Nl Akademie Van Wetenschappen Knaw Culture media for stem cells
RU2428956C2 (ru) * 2009-07-13 2011-09-20 Александр Дмитриевич Ромащенко Способ лечения атрофии зрительного нерва посредством трансплантации аутологичных стволовых клеток
US8377432B2 (en) * 2009-09-02 2013-02-19 Khay-Yong Saw Method and composition for neochondrogenesis
AU2010289423B2 (en) * 2009-09-04 2014-03-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for enhancing genome stability and telomere elongation in embryonic stem cells
US20120201791A1 (en) * 2009-10-15 2012-08-09 Tai June Yoo Methods of treating diseases or conditions using mesenchymal stem cells
JP5035737B2 (ja) * 2009-12-07 2012-09-26 国立大学法人名古屋大学 脂肪組織由来間葉系幹細胞を含有する、前立腺癌治療用細胞製剤
EP2555783A1 (en) * 2010-04-08 2013-02-13 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
WO2011145110A1 (en) 2010-05-15 2011-11-24 Subhadra Dravida A novel cord blood plasma nutrient formulation and a method for the preparation thereof
KR101913874B1 (ko) * 2010-11-10 2018-10-31 인리젠 장기 확대를 위한 주사가능 제제
FR2986537B1 (fr) * 2012-02-07 2014-03-28 Oreal Procede d'evaluation d'actif(s) apte(s) a preserver la fonctionnalite des cellules souches epitheliales
US20150079047A1 (en) * 2012-04-16 2015-03-19 The Regents Of The University Of California Ocular therapeutics using embryonic stem cell microvesicles
WO2014089121A2 (en) * 2012-12-03 2014-06-12 Thomas Ichim Retrograde delivery of cells and nucleic acids for treatment of cardiovascular diseases
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US20150335714A1 (en) * 2013-01-25 2015-11-26 Tammy Z. Movsas Use of human chorionic gonadotropin to inhibit development or minimize severity of cerebral palsy and/or its co-morbidities
CN103961373A (zh) * 2013-02-04 2014-08-06 西比曼生物科技（上海）有限公司 异体间质血管层细胞和异体间充质祖细胞在预防或治疗骨性关节炎中的应用
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
ITMI20130513A1 (it) * 2013-04-05 2014-10-06 Euroclone S P A Metodo diagnostico per patologie autoimmuni del fegato
WO2015173425A1 (en) 2014-05-16 2015-11-19 Koninklijke Nederlandse Akademie Van Wetenschappen Improved culture method for organoids
KR101686315B1 (ko) 2015-01-09 2016-12-13 이화여자대학교 산학협력단 편도 유래 중간엽 줄기세포로부터 슈반 세포의 분화 방법
KR20160109358A (ko) 2015-03-11 2016-09-21 이화여자대학교 산학협력단 면역 질환 예방 또는 치료용 조성물
KR102036029B1 (ko) 2015-03-11 2019-10-24 이화여자대학교 산학협력단 골수 부전 예방 또는 치료용 조성물
KR20160109356A (ko) 2015-03-11 2016-09-21 이화여자대학교 산학협력단 자가 면역 질환 예방 또는 치료용 조성물
US10870830B2 (en) 2015-03-26 2020-12-22 EWHA University—Industry Collaboration Foundation Method for culturing differentiation-promoting and -sustaining spheroid form of tonsil-derived stem cells
EP4070803B1 (en) 2015-06-01 2025-10-08 Memorial Sloan-Kettering Cancer Center Methods of in vitro differentiation of midbrain dopamine (mda) neurons
WO2017112901A1 (en) 2015-12-23 2017-06-29 Memorial Sloan-Kettering Cancer Center Cell-based treatment and drug discovery in hirschsprung's disease enabled by pluripotent stem cell-derived human enteric neural crest lineages
AU2017214749B2 (en) 2016-02-05 2024-03-28 Memorial Sloan-Kettering Cancer Center Methods of differentiating stem cell-derived ectodermal lineage precursors
CN105749254A (zh) * 2016-02-28 2016-07-13 深圳爱生再生医学科技有限公司 用于治疗血管性痴呆的干细胞制剂及其制备方法和应用
GB201603569D0 (en) 2016-03-01 2016-04-13 Koninklijke Nederlandse Akademie Van Wetenschappen Improved differentiation method
EP3464567A4 (en) 2016-05-27 2020-01-08 Memorial Sloan Kettering Cancer Center METHOD FOR DIFFERENTIATING PROPRIOZEPTORS FROM STEM CELLS
US12161111B2 (en) * 2016-09-23 2024-12-10 Peter Friedman Compositions and methods for treating citrus plants infected with bacteria and for promoting general agricultural health
CN106177918A (zh) * 2016-09-30 2016-12-07 广州赛莱拉干细胞科技股份有限公司 一种间充质干细胞注射液及其制备方法和应用
JP6942363B2 (ja) * 2017-01-31 2021-09-29 国立大学法人大阪大学 多能性幹細胞の分化制御方法
US11590175B2 (en) 2017-08-23 2023-02-28 Merakris Therapeutics Llc Compositions containing amniotic components and methods for preparation and use thereof
ES3023522T3 (en) 2017-11-16 2025-06-02 Aivita Biomedical Inc Use of cell membrane-bound signaling factors
GB201721615D0 (en) 2017-12-21 2018-02-07 Koninklijke Nederlandse Akademie Van Wetenschappen Immune cell organoid co-cultures
KR102130493B1 (ko) 2018-07-11 2020-07-06 이화여자대학교 산학협력단 건선 예방 또는 치료용 조성물
KR102089476B1 (ko) 2018-07-11 2020-03-16 이화여자대학교 산학협력단 피부 염증 질환 예방 또는 치료용 조성물
GB201819224D0 (en) 2018-11-26 2019-01-09 Koninklijke Nederlandse Akademie Van Wetenschappen Hepatocyte expansion methods
KR20220012220A (ko) 2019-02-28 2022-02-03 메라크리스 테라퓨틱스 엘엘씨 양수 유래 세포외 소포체 및 상처 치유를 위한 이의 용도
KR20190120141A (ko) 2019-10-16 2019-10-23 이화여자대학교 산학협력단 골수 부전 예방 또는 치료용 조성물
KR20210119766A (ko) * 2020-03-25 2021-10-06 서울대학교병원 인간 배아줄기세포 유래 중간엽 줄기세포를 포함하는 망막색소변성의 예방 또는 치료용 약학적 조성물
IL299405A (en) 2020-06-26 2023-02-01 Minerva Biotechnologies Corp Methods for deriving dopaminergic neurons from pluripotent stem cells
US12129483B2 (en) 2020-12-18 2024-10-29 University Of Georgia Research Foundation, Inc. Compositions and methods for making sensory neurons
CN117500916A (zh) 2021-04-16 2024-02-02 博恩赛尔公司 制备、扩增和纯化中脑多巴胺能祖细胞的方法
CN113116933A (zh) * 2021-04-26 2021-07-16 河北医科大学第四医院 一种防治糖尿病足的干细胞组合物及其应用
CN114600872A (zh) 2022-04-13 2022-06-10 西安北光医学生物技术有限公司 一种细胞、组织或器官的抗损伤保存的方法及保存系统
WO2024177863A1 (en) * 2023-02-20 2024-08-29 Intabio, Llc Mass spectrometry calibration methods

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744347A (en) 1987-01-16 1998-04-28 Ohio University Edison Biotechnology Institute Yolk sac stem cells and their uses
DE68928914T2 (de) 1988-08-04 1999-09-09 Amrad Corp. Ltd. (in vitro)-vermehrung von embryonalen stammzellen unter verwendung von leukämie-inhibitionsfaktor (lif)
US5256560A (en) 1988-10-07 1993-10-26 University Of Saskatchewan Primitive cell colony stimulating factors and lymphohematopoietic progenitor cells
US5411883A (en) 1989-12-26 1995-05-02 Somatix Therapy Corporation Proliferated neuron progenitor cell product and process
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5622853A (en) 1990-05-01 1997-04-22 Becton Dickinson And Company T lymphocyte precursor
US5840580A (en) 1990-05-01 1998-11-24 Becton Dickinson And Company Phenotypic characterization of the hematopoietic stem cell
ATE181746T1 (de) 1990-09-10 1999-07-15 Takeda Chemical Industries Ltd Menschlicher rezeptor für luteinisierendes hormon und choriongonadotropin
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5851832A (en) 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US6410320B1 (en) 1992-03-02 2002-06-25 The University Of Michigan Method and compositions for isolation and growth of kidney tubule stem cells, in vitro kidney tubulogenesis and ex vivo construction of renal tubules
WO1993018648A1 (en) 1992-03-23 1993-09-30 Baxter International Inc. In vitro-derived human neutrophil precursor cells
WO1994000484A1 (en) 1992-06-22 1994-01-06 Young Henry E Scar inhibitory factor and use thereof
US5589376A (en) 1992-07-27 1996-12-31 California Institute Of Technology Mammalian neural crest stem cells
US5453357A (en) 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5690926A (en) 1992-10-08 1997-11-25 Vanderbilt University Pluripotential embryonic cells and methods of making same
AU5603894A (en) 1992-11-16 1994-06-08 Applied Immune Sciences, Inc. Pluripotential quiescent stem cell population
DE4240635C2 (de) 1992-12-03 1997-07-10 Lothar Prof Dr Kanz Vermehrung hämatopoetischer Vorläuferzellen ex vivo sowieZusammensetzungen hämatopoetischer Wachstumsfaktoren
EP0722331A4 (en) 1993-08-25 1997-10-01 Systemix Inc METHOD FOR PRODUCING A POPULATION OF HIGHLY ENRICHED HEMATOPOIETIC STEM CELLS
US5453457A (en) 1993-11-12 1995-09-26 Bayer Corporation Gamma-radiation-resistant polycarbonate composition
US5972627A (en) 1994-06-15 1999-10-26 Systemix, Inc. Method of purifying a population of cells enriched for dendritic and/or lymphoid progenitors and populations of cells obtained thereby
US5650317A (en) 1994-09-16 1997-07-22 Michigan State University Human breast epithelial cell type with stem cell and luminal epithelial cell characteristics
US5677136A (en) 1994-11-14 1997-10-14 Systemix, Inc. Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
US5874301A (en) 1994-11-21 1999-02-23 National Jewish Center For Immunology And Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5914268A (en) 1994-11-21 1999-06-22 National Jewish Center For Immunology & Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5821108A (en) 1995-04-07 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Enrichment for a thymocyte subset having progenitor cell activity using c-kit as a selection marker
US5876956A (en) 1995-05-15 1999-03-02 Johns Hopkins University School Of Medicine Methods for identification or purification of cells containing an enzymatic intracellular marker
US5908782A (en) 1995-06-05 1999-06-01 Osiris Therapeutics, Inc. Chemically defined medium for human mesenchymal stem cells
US6517872B1 (en) 1995-06-12 2003-02-11 Yeda Research And Development Co., Ltd. FGFR3 as a marker for mesenchymal skeletal progenitor cells
US5753505A (en) 1995-07-06 1998-05-19 Emory University Neuronal progenitor cells and uses thereof
GB9514816D0 (en) 1995-07-19 1995-09-20 Ucli Ltd Substances and their medical use
US5858782A (en) 1995-11-13 1999-01-12 Regents Of The University Of Michigan Functional human hematopoietic cells
US5997871A (en) 1996-06-24 1999-12-07 University Of Maryland Biotechnology Insitute Treatment and prevention of cancer by administration of derivatives of human chorionic gonadotropin
US6969608B1 (en) 1996-08-26 2005-11-29 Mcgill University Pharmaceuticals containing multipotential precursor cells from tissues containing sensory receptors
US6890724B2 (en) 1996-09-06 2005-05-10 California Institute Of Technology Methods and compositions for neural progenitor cells
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
CA2216439A1 (en) 1996-09-25 1998-03-25 Derek Van Der Kooy Pharmaceuticals containing retinal stem cells
AU5734998A (en) 1997-01-10 1998-08-03 Life Technologies, Inc. Embryonic stem cell serum replacement
US6331406B1 (en) 1997-03-31 2001-12-18 The John Hopkins University School Of Medicine Human enbryonic germ cell and methods of use
US6090622A (en) 1997-03-31 2000-07-18 The Johns Hopkins School Of Medicine Human embryonic pluripotent germ cells
US6583109B1 (en) 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
US6734015B1 (en) 1997-07-04 2004-05-11 University Of Utah Research Foundation Isolation of lineage-restricted neuronal precursors
US6908763B1 (en) 1997-08-22 2005-06-21 The Board Of Trustees Of The Leland Stanford Junior University Mammalian common lymphoid progenitor cell
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6245757B1 (en) 1997-10-03 2001-06-12 Research Corporation Technologies, Inc. Use of progestins to treat ischemic event
EP1025204A4 (en) 1997-10-23 2001-02-28 Geron Corp Methods and materials for the growth of primate-derived primordial stem cells
JP2001525176A (ja) 1997-12-04 2001-12-11 デューク・ユニバーシティー Ｃｄ７＋ｃｄ３４−ｌｉｎ−造血細胞を単離し、使用する方法
WO1999037751A1 (en) 1998-01-23 1999-07-29 Imclone Systems Incorporated Purified populations of stem cells
AUPP244498A0 (en) 1998-03-18 1998-04-09 Medvet Science Pty. Ltd. Keratinocyte stem cells
US6812027B2 (en) 1998-03-25 2004-11-02 Cornell Research Foundation, Inc. Discovery, localization, harvest, and propagation of an FGF2 and BDNF-responsive population of neural and neuronal progenitor cells in the adult human forebrain
US6835567B1 (en) 1998-04-14 2004-12-28 Signal Pharmaceuticals, Inc. PNS cell lines and methods of use therefor
US6387367B1 (en) 1998-05-29 2002-05-14 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6129911A (en) 1998-07-10 2000-10-10 Rhode Island Hospital, A Lifespan Partner Liver stem cell
US6913925B1 (en) 1998-08-12 2005-07-05 Signal Pharmaceuticals Llc Human mesencephalon cell lines and methods of use therefor
DE19837438A1 (de) 1998-08-18 2000-02-24 Biotechnolog Forschung Gmbh Rekombinante Humanzelle für Knochen- und Knorpelzellbildung
US6767737B1 (en) 1998-08-31 2004-07-27 New York University Stem cells bearing an FGF receptor on the cell surface
US6667176B1 (en) * 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
AU2969899A (en) 1998-12-16 2000-07-03 Tsentr Embrionalnykh Tkanei "Emcell" Method for treating patients using cellular suspensions of embryonic tissues
EP1156822B1 (en) 1999-02-24 2006-02-08 Novo Nordisk A/S Iin vitro method for synchronisation of oocyte maturation
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
EP1173587A1 (en) 1999-04-23 2002-01-23 Ceptyr, Inc. Dsp-10 dual-specificity map kinase phosphatase
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6761883B2 (en) 1999-06-29 2004-07-13 The Board Of Trustees Of The Leland Stanford Junior University Mammalian myeloid progenitor cell subsets
CA2375974C (en) 1999-06-29 2010-11-02 The Board Of Trustees Of The Leland Stanford Junior University Mammalian myeloid progenitor cell subsets
US6872389B1 (en) 1999-07-08 2005-03-29 Rhode Island Hospital Liver stem cell
US6043235A (en) 1999-07-21 2000-03-28 Research Triangle Institute 11β-aryl-17, 17-spirothiolane-substituted steroids
WO2002064748A2 (en) 2001-02-14 2002-08-22 Furcht Leo T Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
AU7378600A (en) * 1999-09-14 2001-04-17 Children's Medical Center Corporation Methods for treating muscular dystrophy
CA2386559A1 (en) * 1999-09-14 2001-03-22 The Children's Medical Center Corporation Isolation of muscle-derived stem cells and uses therefor
US20030082155A1 (en) 1999-12-06 2003-05-01 Habener Joel F. Stem cells of the islets of langerhans and their use in treating diabetes mellitus
EP1240518A4 (en) 1999-12-13 2006-05-17 Scripps Research Inst MARKERS TO IDENTIFY AND ISOLATE PROGENITORS OF PANCREATIC ISLAND ALPHA AND BETA CELLS
US6416999B1 (en) 2000-04-07 2002-07-09 Raven Biotechnologies, Inc. Human Müllerian duct-derived epithelial cells and methods of isolation and uses thereof
US6436704B1 (en) 2000-04-10 2002-08-20 Raven Biotechnologies, Inc. Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
CA2405345C (en) 2000-04-25 2012-09-18 Osiris Therapeutics, Inc. Joint repair using mesenchymal stem cells
NL1017973C2 (nl) 2000-05-10 2002-11-08 Tristem Trading Cyprus Ltd Inrichting.
US6936281B2 (en) 2001-03-21 2005-08-30 University Of South Florida Human mesenchymal progenitor cell
WO2002018549A1 (en) * 2000-08-30 2002-03-07 Maria Biotech Co., Ltd. Human embryonic stem cells derived from frozen-thawed embryo
US20040071665A1 (en) 2000-09-05 2004-04-15 Yong-Fu Xiao Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal
US6458588B1 (en) 2001-01-31 2002-10-01 The General Hospital Corporation Renal stem cells and uses thereof
US6852532B2 (en) 2001-03-21 2005-02-08 University Of Utah Research Foundation Method of isolating human neuroepithelial precursor cells from human fetal tissue
EP1385935A4 (en) * 2001-03-29 2004-09-15 Ixion Biotechnology Inc METHOD FOR TRANSDIFFERENTIATION OF NON-PANCREATIC STEM CELLS IN THE PANCREAS DIFFERENTIATION PATHWAY
US20030017587A1 (en) 2001-07-18 2003-01-23 Rader William C. Embryonic stem cells, clinical applications and methods for expanding in vitro
DE10139783C1 (de) * 2001-08-14 2003-04-17 Transtissue Technologies Gmbh Zellzusammensetzungen zur Behandlung von Osteoarthrose, sowie Verfahren zu deren Herstellung
HUP0501094A2 (en) * 2001-11-06 2006-04-28 Univ Shanghai 2Nd Medical Somatic cell derived embryonic stem cells and its differentiated cells
CA2468171C (en) 2001-11-15 2015-10-06 Children's Medical Center Corporation Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof
CA2468292A1 (en) * 2001-11-26 2003-06-05 Advanced Cell Technology, Inc. Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
IL164079A0 (en) * 2002-03-15 2005-12-18 Us Dept Veterans Affairs Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
US20040009589A1 (en) * 2002-03-26 2004-01-15 Shulamit Levenberg Endothelial cells derived from human embryonic stem cells
US7285415B2 (en) * 2002-07-11 2007-10-23 The Regents Of The University Of California Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury
ES2376866T3 (es) 2002-07-25 2012-03-20 The Scripps Research Institute Células troncales hemotopoyéticas y procedimientos de tratamiento de las enfermedades oculares noeovasculares con las mismas
NZ539713A (en) * 2002-10-11 2008-07-31 Novocell Inc Implantation of encapsulated biological materials for treating diseases
JP2006508076A (ja) 2002-10-11 2006-03-09 リガンド・ファーマシューティカルズ・インコーポレイテッド 選択的プロゲステロン受容体モジュレーター化合物としての５−シクロアルケニル５Ｈ−クロメノ［３，４−ｆ］キノリン誘導体
MXPA05003800A (es) 2002-10-11 2005-06-08 Ligand Pharm Inc 5-(1¦,1¦-cicloalquil/alquenil)metiliden 1,2-dihidro-5h- cromeno[3,4f]quinolinas como compuestos moduladores de receptor de progesterona selectivos.
AU2003285172A1 (en) 2002-11-08 2004-06-03 The Johns Hopkins University Human embryonic stem cell cultures, and compositions and methods for growing same
UA59678A (uk) 2002-11-15 2003-09-15 Національний Медичний Університет Ім. О.О. Богомольця Спосіб лікування ревматоїдного артриту
KR100763477B1 (ko) * 2003-03-12 2007-10-04 리라이언스 라이프 사이언시스 프라이빗. 리미티드 사람 배아 줄기세포로부터 최종적으로 분화된 도파민작용성 뉴런의 유도
KR20080109943A (ko) 2003-08-29 2008-12-17 위스콘신 얼럼나이 리서어치 화운데이션 영장류 배아 줄기 세포 기원의 신경 줄기 세포, 운동 뉴런 및 도파민 뉴런의 시험관내 분화 방법
WO2005047524A2 (en) 2003-11-10 2005-05-26 The Scripps Research Institute Compositions and methods for inducing cell dedifferentiation
US20050106554A1 (en) 2003-11-19 2005-05-19 Palecek Sean P. Cryopreservation of pluripotent stem cells
UA71388A (uk) 2003-12-26 2004-11-15 Інститут Нейрохірургії Імені Академіка А. П. Ромоданова Академії Медичних Наук України Спосіб отримання збагаченої суспензії стовбурових нейральних клітин
US20050233446A1 (en) 2003-12-31 2005-10-20 Parsons Xuejun H Defined media for stem cell culture
GB2441530B (en) 2004-02-12 2009-09-23 Univ Newcastle Stem Cells
WO2005099758A2 (en) * 2004-04-17 2005-10-27 The Board Of Trustees The Leland Standford Junior University Injectable bioartificial tissue matrix
EP1812556A4 (en) 2004-10-05 2011-02-02 Univ Georgia NEURONAL PROGENITORS OBTAINED BY CULTURE OF HUMAN EMBRYONIC STEM CELLS WITHOUT NOURISHING CELLS
EP2422794A3 (en) 2006-03-07 2013-03-13 Geeta Shroff Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation

Also Published As

Publication number Publication date
US8592208B2 (en) 2013-11-26
EA200801943A1 (ru) 2009-04-28
EP2422802A2 (en) 2012-02-29
WO2007141657B1 (en) 2008-07-31
DK1993575T3 (da) 2019-10-14
JP2009528834A (ja) 2009-08-13
EP2422801A2 (en) 2012-02-29
EP2422797A3 (en) 2013-03-20
US9804151B2 (en) 2017-10-31
CN101420964A (zh) 2009-04-29
CA2644922A1 (en) 2007-12-13
ECSP088799A (es) 2008-12-30
NO20084181L (no) 2008-11-26
US9482660B2 (en) 2016-11-01
KR20080106332A (ko) 2008-12-04
EA027648B1 (ru) 2017-08-31
GEP20135796B (en) 2013-04-10
BRPI0708576A2 (pt) 2011-05-31
US9488643B2 (en) 2016-11-08
MX2008011279A (es) 2008-11-25
US20140057350A1 (en) 2014-02-27
EP2422803A3 (en) 2013-03-13
KR101505202B1 (ko) 2015-03-27
CR10345A (es) 2009-03-30
CN103893211A (zh) 2014-07-02
EP2422801A3 (en) 2013-03-06
EP2422799A2 (en) 2012-02-29
EP2422802A3 (en) 2013-03-06
NZ594639A (en) 2013-04-26
EP2422794A2 (en) 2012-02-29
US20140051164A1 (en) 2014-02-20
CA2644922C (en) 2019-07-23
EP2422798A3 (en) 2013-03-06
US8900861B2 (en) 2014-12-02
EP2422794A3 (en) 2013-03-13
IL193702A0 (en) 2011-08-01
EP2422803A2 (en) 2012-02-29
MX347303B (es) 2017-04-21
EP2422799A3 (en) 2013-03-06
US20130122588A1 (en) 2013-05-16
EP1993575B1 (en) 2019-07-03
MY154677A (en) 2015-07-15
US20140051110A1 (en) 2014-02-20
EP2422796A2 (en) 2012-02-29
US20140050706A1 (en) 2014-02-20
NZ571127A (en) 2012-01-12
WO2007141657A2 (en) 2007-12-13
PH12014501028A1 (en) 2016-02-22
US20130122486A1 (en) 2013-05-16
EP2422798A2 (en) 2012-02-29
US20090123433A1 (en) 2009-05-14
US9134299B2 (en) 2015-09-15
AU2007257594B2 (en) 2012-11-01
US10545135B2 (en) 2020-01-28
EP2422795A2 (en) 2012-02-29
JP5649786B2 (ja) 2015-01-07
EP2422795A3 (en) 2013-03-13
EP1993575A2 (en) 2008-11-26
US20190369088A1 (en) 2019-12-05
EA027648B9 (ru) 2018-01-31
AP2949A (en) 2014-07-31
KR101505382B1 (ko) 2015-03-23
WO2007141657A3 (en) 2008-04-24
IL193702A (en) 2015-02-26
MA30323B1 (fr) 2009-04-01
AP2008004623A0 (en) 2008-10-31
EP2422796A3 (en) 2013-03-13
EP2422797A2 (en) 2012-02-29
JP2014159455A (ja) 2014-09-04
KR20140135263A (ko) 2014-11-25
US9383349B2 (en) 2016-07-05
AU2007257594A1 (en) 2007-12-13
EP2422800A3 (en) 2013-03-06
US20140057250A1 (en) 2014-02-27
EP2422800A2 (en) 2012-02-29

Similar Documents

Publication Publication Date Title
CU20080161A7 (es) Composiciones que comprenden células madres de tejidos seleccionados y métodos de preparación
ES2741806T3 (es) Un método para la diferenciación directa de células madre pluripotentes en músculo cardíaco funcional
JP7593577B2 (ja) アミノ酸組成物及びその使用
BR112014015720A8 (pt) derivados de tieno[3,2-d]pirimidina que têm atividade inibidora de proteinas quinases
TNSN08165A1 (en) Agricultural composition
NI201200172A (es) Activadores de guanilato ciclasa soluble
BR112014018524A8 (pt) Derivados de pirimido [4,5-b]indol, seus usos, composição farmaceutica, e método in vivo ou ex vivo para aumentar as células estaminais e/ou progenitoras
KR20180037967A (ko) 배양 배지
WO2003065999A3 (en) Proliferated cell lines and uses thereof
WO2011043629A3 (ko) 인간 지방 줄기세포의 고활성을 유도하는 방법 및 배지
ES2377194T3 (es) Suplemento de medios de cultivo de gametos y de embriones de mamíferos y procedimiento de utilización del mismo
WO2010108058A3 (en) Small molecule inhibitors of dusp6 and uses therefor
KR102121042B1 (ko) 조류의 에그로부터 분리한 세포인 배반엽 전분화능세포, 신경줄기세포, 배아섬유아세포 컨디션드 배지를 유효성분으로 하는 세포 증식, 피부재생 및 주름 개선용 배지 조성물
JP2021520351A (ja) 皮膚を治療するための組成物
BR112012016128A8 (pt) Agente terapêutico (y-39983) para disfunção endotelial da córnea
WO2011037416A3 (ko) 세포이식술을 위한 혼합세포복합체인 세포스페로이드의 제조방법 및 이의 이용방법
KR20160006127A (ko) 줄기세포의 보관 안정성 증진용 조성물
CU20130075A7 (es) Composición farmacéutica que comprende células madre humanas y sus derivados y métodos de preparación
UA99813C2 (ru) Композиция человеческих эмбриональных стволовых клеток или их производных, способы применения и способы получения (варианты)
CN100432219C (zh) 一种含茶多酚的牛卵母细胞体外成熟培养液及其培养方法
Bukovsky et al. Ovarian germ cells
WO2018215684A1 (es) Medios de cultivo con lisados plaquetarios
KR101849631B1 (ko) 에그 세포 배양액을 유효성분으로 포함하는 인간 줄기세포 성장용 배지 조성물
MX2012012672A (es) Gen y proteina acc sintasa 3 de maiz y sus usos.
Malathi et al. Role of Aluminium and Phosphorus on the Secretion and Behaviour of Acid Phosphatase in Callus Culture of Brassica juncea